SCHEMBL2368841

SCHEMBL2368841

Cc1cccc(CNc2ncnc3sc(Br)c(-c4ccccc4)c23)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.44
TNF P01375 1/20 0.44
NOD1 Q9Y239 1/20 0.44
CSNK2A2 P19784 3/20 0.42
CSNK2B P67870 3/20 0.42
CSNK2A1 P68400 3/20 0.42
FGFR1 P11362 1/20 0.42
EGFR P00533 2/20 0.41
LMNA P02545 1/20 0.41
GFER P55789 1/20 0.41
PIP4K2C Q8TBX8 1/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
RAB9A P51151 1/20 0.39
ALDH1A1 P00352 2/20 0.38
MAPT P10636 2/20 0.38
ESR1 P03372 1/20 0.38
POLB P06746 1/20 0.38
ALOX15 P16050 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2369027 0.89 FGFR1 (0.54) MAPK1TNFNOD1CSNK2A2CSNK2B
SCHEMBL3382778 0.84 TNF (0.61) MAPK1TNFNOD1EGFRLMNA
SCHEMBL3383452 0.78 MAPK1 (0.72) MAPK1TNFNOD1CSNK2A2CSNK2B
SCHEMBL3387014 0.76 SMN1; SMN2 (0.60) MAPK1LMNASMN1; SMN2MEN1KMT2A
SCHEMBL3384562 0.76 TNF (0.61) MAPK1TNFNOD1CSNK2A2CSNK2B
SCHEMBL3382567 0.72 FGFR1 (0.54) MAPK1TNFNOD1CSNK2A2CSNK2B
SCHEMBL2369221 0.70 PRKCI (0.43) CSNK2A2CSNK2BCSNK2A1FGFR1LMNA
SCHEMBL2368869 0.69 PRKCI (0.43) CSNK2A2CSNK2BCSNK2A1FGFR1EGFR
SCHEMBL2368043 0.69 PRKCI (0.45) MAPK1CSNK2A2CSNK2BCSNK2A1FGFR1
SCHEMBL2368222 0.68 PRKCI (0.41) CSNK2A2CSNK2BCSNK2A1FGFR1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8022076-B2 Thieno[2,3-d]pyrimidine derivatives as potassium channel modulators; antiarrhythmia agents XENTION LIMITED (GB) 2011-09-20 US disclosed
EP-1641803-B3 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION LTD (GB) 2010-12-08 EP disclosed
EP-1641803-B1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION LTD (GB) 2009-03-18 EP disclosed
CN-1823071-A Thienopyrimidine derivatives as potassium channel inhibitors XENTION DISCOVERY LTD (GB) 2006-08-23 CN disclosed
US-20050026935-A1 Compounds XENTION DISCOVERY LTD. 2005-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026935-A1 Compounds KCNJ11, KCNJ1, KCNH1 MAPK1 667/4885TNF 2689/4885NOD1 2052/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.